Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.4317
-0.0005 (-0.12%)
At close: Jun 20, 2025, 4:00 PM
0.4299
-0.0018 (-0.42%)
After-hours: Jun 20, 2025, 7:36 PM EDT
Cosmos Health Revenue
Cosmos Health had revenue of $13.71M in the quarter ending March 31, 2025, a decrease of -5.98%. This brings the company's revenue in the last twelve months to $53.55M, down -3.70% year-over-year. In the year 2024, Cosmos Health had annual revenue of $54.43M with 1.97% growth.
Revenue (ttm)
$53.55M
Revenue Growth
-3.70%
P/S Ratio
0.17
Revenue / Employee
$359,426
Employees
149
Market Cap
12.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.43M | 1.05M | 1.97% |
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
COSM News
- 5 weeks ago - RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - GlobeNewsWire
- 5 weeks ago - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - GlobeNewsWire
- 6 weeks ago - Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units - GlobeNewsWire
- 6 weeks ago - Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq - GlobeNewsWire
- 7 weeks ago - Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 - GlobeNewsWire
- 2 months ago - Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million - GlobeNewsWire
- 2 months ago - Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L - GlobeNewsWire
- 2 months ago - Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order - GlobeNewsWire